Open AccessA Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines: A Focus on Safety From the SAKURA 3 Study
Author(s) -
Jeremy B. Green,
Kavita Mariwalla,
Kyle Coleman,
Glynis Ablon,
Susan H. Weinkle,
Conor J. Gallagher,
Domenico Vitarella,
Roman G. Rubio
Publication year - 2020
Publication title -
dermatologic surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.659
H-Index - 125
eISSN - 1524-4725
pISSN - 1076-0512
DOI - 10.1097/dss.0000000000002463
Subject(s) - medicine , adverse effect , eyelid , placebo , safety profile , clinical trial , surgery , ptosis , dermatology , pathology , alternative medicine
SAKURA 3 was a Phase 3, open-label, repeat-dose safety study of DaxibotulinumtoxinA for Injection (DAXI); a component of the largest Phase 3 clinical development program of an aesthetic neuromodulator in glabellar lines.